Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Norene Keenan"'
Autor:
Simona Conte, Sudhir Tauro, Jacqueline Boultwood, Erica Travaglino, Peter J. Campbell, Michael J. Groves, Norene Keenan, Eva Hellström-Lindberg, Elli Papaemmanuil, Anna L. Godfrey, Mario Cazzola, P. Andrew Futreal, Jonathan Hinton, Ann Hyslop, Cristiana Pascutto, Ilaria Ambaglio, Matteo G. Della Porta, Luca Malcovati, James S. Wainscoat, Anna Gallì, Matteo Claudio Da Via, David T. Bowen, Michael R. Stratton, Laura Mudie
In a previous study, we identified somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in patients with myelodysplastic syndrome (MDS). Here, we define the clinical significance of these mutations in MDS and myelod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf688117f0ac580792b39f9cfdfbfbd4
https://doi.org/10.1182/blood-2011-09-377275
https://doi.org/10.1182/blood-2011-09-377275
Autor:
Ann Hyslop, Norene Keenan, David T. Bowen, Sudhir Tauro, Michael J. Groves, Senthilkumar Durairaj
Publikováno v:
British Journal of Haematology. 161:280-282
Autor:
Senthilkumar Durairaj, Michael J. Groves, Ann Hyslop, Stephen Chew, Norene Keenan, Sudhir Tauro
Publikováno v:
American journal of hematology. 86(5)
Consideration of iron-chelation (IC) in transfusion-dependent patients is recommended in most clinical-practice guidelines on myelodysplastic syndromes (MDS). The financial impact of IC on health-care systems is predicted through economic modeling, b
Autor:
David, Bowen, Ann, Hyslop, Norene, Keenan, Michael, Groves, Dominic, Culligan, Peter, Johnson, Ann, Shaw, Fiona, Geddes, Patricia, Evans, John, Porter, Ivor, Cavill
Publikováno v:
Haematologica. 91(5)
We randomized 21 patients with low-risk myelodysplastic syndromes (MDS) to receive a single subcutaneous bolus of recombinant erythropoietin (epoietin) +/- granulocyte-colony stimulating factor (G-CSF), or placebo and monitored erythropoietic respons
Autor:
David T. Bowen, Michael J. Groves, Ann Shaw, Dominic Culligan, Peter R. E. Johnson, Fiona Geddes, I. Cavill, Norene Keenan, Ann Hyslop, Patricia Evans, John B. Porter
Publikováno v:
Blood. 104:1435-1435
Recombinant Erythropoietin (+/− G-CSF) is an effective therapy for the anaemia of selected patients with MDS. Validated response prediction models are available, but response rates are only 60% in the “high” predicted response group. Furthermor
Autor:
Ilaria Ambaglio, Erica Travaglino, Nicholas C.P. Cross, David G. Bowen, Jacqueline Boultwood, Norene Keenan, Peter J. Campbell, Anthony R. Green, Michael J. Groves, Michael R. Stratton, Sudhir Tauro, Elli Papaemmanuil, Anna L. Godfrey, James S. Wainscoat, Ann Hyslop, Luca Malcovati, Eva Hellström-Lindberg, Anna Gallì, Paresh Vyas, Andrea Pellagatti, P. Andrew Futreal, Jonathan Hinton, Carlo Gambacorti Passerini, Cristiana Pascutto, Matteo G. Della Porta, Laura Mudie, Simona Conte, Mario Cazzola
Publikováno v:
Publons
Abstract 3 Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by dysplasia in one or more cell lines, ineffective hematopoiesis, and variable risk of progression to acute myeloid leukemia (AML). As any other neoplasm, MDS is expected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb02cdd9df9dbe4c3c2d8c4d136b1499
https://publons.com/publon/21575082/
https://publons.com/publon/21575082/